Cardiac myofibroblasts in autoimmune-associated CHB

自身免疫相关慢性乙型肝炎中的心肌成纤维细胞

基本信息

项目摘要

DESCRIPTION (provided by applicant): A role for anti-SSA/Ro-SSB/La antibodies in the pathogenesis of congenital heart block (CHB) is well established. The scenario involves injury at the atrioventricular (AV) node which progresses through stages, with the final outcome being fibrosis of the node and irreversible third degree block. The proposed studies will examine the possibility that cardiac fibroblasts are a "fetal factor" in the pathogenesis of autoimmune-associated CHB. Under normal circumstances, the fibroblast maintains the cardiac tissue's viscoelasticity, a passive attribute which is provided by elastin and Collagen derived from tissue fibroblasts. In addition, normally a fetus heals without scarring, and during wound healing the fibroblast transiently becomes a myofibroblast which is involved in a maturation of granulation tissue. The proposed studies will determine whether a persistent activation of the fibroblast (i.e., transdifferentiation to a persistent myofibroblast) participates in an effector phase in the autoantibody mediated injury, where the fibroblast switches from normal maintenance to a pathophysiological role leading to the ultimate replacement of the AV node by fibrotic tissue. The experiments in Specific Aim 1 are designed to address the capacity of anti-SSA/Ro-SSB/La antibodies to induce readouts which relate to fibrosis (fibroblast activation and proliferation). Specific Aim 2 will determine whether the abnormal fibroblast phenotype (i.e., myofibroblast) is mirrored by abnormal signal transduction by small GTPases Racl and RhoA. Specific Aim will examine whether injury induced by maternal autoantibodies initiates the persistence of cardiac myofibroblasts in an in vivo model exploiting transgenic mice that express human 52beta Ro ribonucleoprotein in the heart. Establishing whether the transdifferentiation of cardiac fibroblasts into unchecked proliferating myofibroblasts constitutes a "fetal factor" in autoimmune CHB may provide insights into the mechanism of autoantibody-mediated tissue injury in this life-threatening clinical problem.
描述(由申请方提供):抗SSA/Ro-SSB/La抗体的作用 在先天性心脏传导阻滞(CHB)的发病机制中,的 这种情况涉及房室结(AV)损伤, 通过阶段,与最终的结果是纤维化的节点, 不可逆性三度传导阻滞拟议的研究将审查 心脏成纤维细胞可能是发病机制中的“胎儿因素” 自身免疫相关的慢性乙型肝炎在正常情况下,成纤维细胞 维持心脏组织的粘弹性,这是一种被动属性, 由来自组织成纤维细胞的弹性蛋白和胶原蛋白提供。此外,本发明还提供了一种方法, 正常情况下,胎儿愈合时不会留下疤痕,在伤口愈合过程中, 成纤维细胞瞬时变成肌成纤维细胞,其参与肌成纤维细胞的形成。 肉芽组织成熟。拟议的研究将确定是否 成纤维细胞的持续活化(即,转分化为 持久性肌成纤维细胞)参与自身抗体的效应期 介导的损伤,其中成纤维细胞从正常维持转换为 病理生理作用导致房室结最终被 纤维组织具体目标1中的实验旨在解决 抗SSA/Ro-SSB/La抗体诱导读出的能力, 纤维化(成纤维细胞活化和增殖)。具体目标2将 确定异常成纤维细胞表型(即,肌成纤维细胞)是 反映为小GTP酶Racl和RhoA的异常信号转导。 Specific Aim将检查母体自身抗体是否诱导损伤 在体内模型中启动心脏肌成纤维细胞的持续存在 利用表达人52 β Ro核糖核蛋白的转基因小鼠, 心脏确定心脏成纤维细胞的转分化是否 不受控制地增殖的肌成纤维细胞构成了一种“胎儿因素”, 自身免疫性CHB可能提供了对自身抗体介导的机制的见解, 组织损伤在这个危及生命的临床问题。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROBERT M CLANCY其他文献

ROBERT M CLANCY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROBERT M CLANCY', 18)}}的其他基金

Project 1: Profiling anti-Ro preclinical and clinical autoimmunity
项目 1:分析抗 Ro 临床前和临床自身免疫
  • 批准号:
    10004505
  • 财政年份:
    2017
  • 资助金额:
    $ 7.5万
  • 项目类别:
Project 1: Profiling anti-Ro preclinical and clinical autoimmunity
项目 1:分析抗 Ro 临床前和临床自身免疫
  • 批准号:
    10249213
  • 财政年份:
    2017
  • 资助金额:
    $ 7.5万
  • 项目类别:
Endothelial reactivity and nitric oxide synthetase activity in the ALMS (Aspreva
ALMS 中的内皮反应性和一氧化氮合成酶活性 (Aspreva
  • 批准号:
    7224498
  • 财政年份:
    2006
  • 资助金额:
    $ 7.5万
  • 项目类别:
Endothelial reactivity and nitric oxide synthetase activity in the ALMS (Aspreva
ALMS 中的内皮反应性和一氧化氮合成酶活性 (Aspreva
  • 批准号:
    7485056
  • 财政年份:
    2006
  • 资助金额:
    $ 7.5万
  • 项目类别:
Endothelial reactivity and nitric oxide synthetase activity in the ALMS (Aspreva
ALMS 中的内皮反应性和一氧化氮合成酶活性 (Aspreva
  • 批准号:
    7672271
  • 财政年份:
    2006
  • 资助金额:
    $ 7.5万
  • 项目类别:
Endothelial reactivity and nitric oxide synthetase activity in the ALMS (Aspreva
ALMS 中的内皮反应性和一氧化氮合成酶活性 (Aspreva
  • 批准号:
    7289756
  • 财政年份:
    2006
  • 资助金额:
    $ 7.5万
  • 项目类别:
CHILDHOOD ABSENCE EPILEPSY RX, PK-PD-PHARMACOGENETICS
儿童失神癫痫 RX、PK-PD-药物遗传学
  • 批准号:
    7207768
  • 财政年份:
    2005
  • 资助金额:
    $ 7.5万
  • 项目类别:
Antibody-Induced Injury in Congenital Heart Block
先天性心脏传导阻滞中抗体引起的损伤
  • 批准号:
    6664774
  • 财政年份:
    2002
  • 资助金额:
    $ 7.5万
  • 项目类别:
Cardiac myofibroblasts in autoimmune associated CHB
自身免疫相关慢性乙型肝炎中的心肌成纤维细胞
  • 批准号:
    6441121
  • 财政年份:
    2001
  • 资助金额:
    $ 7.5万
  • 项目类别:
Project 1: Profiling anti-Ro preclinical and clinical autoimmunity
项目 1:分析抗 Ro 临床前和临床自身免疫
  • 批准号:
    9766091
  • 财政年份:
  • 资助金额:
    $ 7.5万
  • 项目类别:

相似海外基金

Autoimmune disorder in hereditary angioedema
遗传性血管性水肿中的自身免疫性疾病
  • 批准号:
    26460654
  • 财政年份:
    2014
  • 资助金额:
    $ 7.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Mechanisms of lymphocyte transmigration across the blood-brain barrier using an in vitro model that mimics blood flow and simulates inflammatory conditions as observed in the most frequent autoimmune disorder of the central nervous system, multiple sclero
使用体外模型模拟血流并模拟在中枢神经系统最常见的自身免疫性疾病多发性硬化症中观察到的炎症状况,从而研究淋巴细胞跨血脑屏障的迁移机制
  • 批准号:
    235301825
  • 财政年份:
    2013
  • 资助金额:
    $ 7.5万
  • 项目类别:
    Research Fellowships
The challenge for the development of therapy for autoimmune disorder by the establishment of artificial thymic medullary organ
人工胸腺髓质器官的建立对自身免疫性疾病治疗发展的挑战
  • 批准号:
    23659241
  • 财政年份:
    2011
  • 资助金额:
    $ 7.5万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了